IMT504 immunotherapy for beta cell regeneration in diabetes treatment
IMT504 is a novel immunotherapy molecule that has demonstrated the ability to regenerate insulin-producing beta cells in multiple mouse diabetes models, enabling complete blood glucose control without additional intervention. MABT is advancing this lead candidate toward canine model validation as a potential treatment for diabetes.
Overview
IMT504 is a proprietary immunotherapy molecule developed by Mid-Atlantic BioTherapeutics (MABT) that has shown the ability to regenerate insulin-producing beta cells in animal models of diabetes. In multiple mouse studies, IMT504-treated animals achieved complete and lasting control of blood glucose levels without any additional therapeutic intervention, while control animals rapidly deteriorated. Treated animals maintained normal body weight, behavior, and overall health with no observable adverse effects, even at the highest tested doses. The therapy works by stimulating tissue repair pathways, enabling the natural restoration of pancreatic beta cell function. This approach represents a fundamentally different treatment paradigm compared to conventional insulin replacement therapies, targeting the underlying cause of beta cell loss rather than managing symptoms.
Technical specifications
Key features:
- Beta cell regeneration: IMT504 promotes the regrowth of functional insulin-producing beta cells, addressing the root cause of certain types of diabetes
- Rapid onset of action: Beneficial effects occur after the first few doses, with marked reversal of diabetes symptoms
- Tissue repair activation: Treatment triggers increases in key repair markers including PCNA, CD31, nestin, and NGN3
- Favorable safety profile: No observable adverse effects or diabetes sequelae in treated animals, even at the highest tested doses
- Sustained efficacy: Data extends beyond two months showing complete blood glucose control
- Immunotherapy mechanism: Harnesses the body's own immune and repair responses to restore pancreatic function
Technology readiness level
IMT504 has been validated in multiple streptozotocin-induced mouse diabetes models, with results published in peer-reviewed literature. The program is currently advancing toward testing in a relevant canine model, which would involve manufacturing a new batch of IMT504 and conducting comprehensive studies including blood glucose monitoring, longitudinal biomarker analysis, metabolomics, and histology to assess beta cell regeneration and function. MABT is a clinical-stage biotechnology company with experience in advancing immunotherapy candidates through regulatory pathways. The company has received Orphan Drug Designation for IMT504 in rabies and is actively seeking strategic partnerships to accelerate development across its pipeline.
About Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics (MABT), founded in 2011 and headquartered in Doylestown, Pennsylvania, is a clinical-stage biotechnology company that utilizes advanced artificial intelligence and proprietary computational methods to drive drug discovery. The company focuses on developing novel immunotherapy solutions for challenging infectious diseases and central nervous system (CNS) disorders. Its lead proprietary technology platform, IMT504, is designed to harness the body's own immune response to treat severe infectious conditions, including rabies, for which it has received Orphan Drug Designation. Additionally, MABT is leveraging structural biology and AI-driven screening, through collaborations such as the one with Accelero BioStructures, to develop USP30 inhibitors aimed at addressing neurological conditions like Parkinson’s and Alzheimer’s disease.
These therapeutic efforts are critical to addressing significant unmet medical needs, particularly where existing treatments are limited or non-existent. By targeting intractable illnesses, MABT seeks to offer new treatment paradigms that can improve patient outcomes and alleviate the burdens of infectious and neurodegenerative diseases. The company’s leadership team comprises experienced scientists and pharmaceutical professionals with expertise in clinical development and commercialization. MABT actively engages in strategic licensing and research partnerships to advance its pipeline and expand its global market presence, supported by ongoing funding initiatives intended to accelerate clinical trials and discovery programs.
delivered to your inbox.